Journal
ADVANCED DRUG DELIVERY REVIEWS
Volume 87, Issue -, Pages 25-34Publisher
ELSEVIER
DOI: 10.1016/j.addr.2015.04.012
Keywords
-
Categories
Funding
- American Cancer Society [DHP-105, RD-324]
- American Foundation for AIDS Research [00638, 00004]
- Florida High Technology and Industry Council
- Genta, Inc.
- Heritable Disease Foundation
- Leukemia Society
- Milligen/Biosearch, Inc.
- US Army Medical Research and Development Command [W81XWH-09-1-0577, DAMD17-86-G-6037]
- US Department of Energy [ER63055]
- US National Institutes of Health [N01 CO027175, R01 CA148565, R21 DA027746, R44 CA136306, R01 CA76290, R01 CA42960, R03 TW01094, U01 CA60139, R01 GM32024, R01 GM28408, R01 GM24128, R01 GM23248]
- US National Science Foundation [BMS 75-17781, PCM 77-25211, PCM 79-23471]
Ask authors/readers for more resources
Synthetic, complementary DNA single strands and short interfering RNA double strands have been found to inhibit the expression of animal, plant, and viral genes in cells, animals, and patients, in a dose dependent and sequence specific manner. DNAs and RNAs, however, are readily digested in biological systems. Hence, chemists are obliged to design and synthesize nuclease-resistant analogs of normal DNA (Fig. 1). (C) 2015 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
